Equity Analysis

Quarterly Results

    Lyka Labs Ltd
    Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
    BSE Code
    ISIN Demat
    Book Value()
    500259
    INE933A01014
    36.6360325
    NSE Symbol
    P/E(TTM)
    Mar.Cap( Cr.)
    LYKALABS
    134.68
    533.57
    EPS(TTM)
    Face Value()
    Div & Yield %:
    1.11
    10
    0
     
Quarters
(RupeeIcon Cr)
ParticularsSep 2024Jun 2024Mar 2024
Gross Sales41.1630.1026.98
Other Operating Income0.000.000.00
Other Income 0.130.620.39
Total Income41.2830.7227.37
Total Expenditure 35.8226.0524.78
PBIDT5.474.672.60
Interest 0.520.651.04
PBDT4.954.021.56
Depreciation1.681.682.77
Tax0.840.400.35
Fringe Benefit Tax0.000.000.00
Deferred Tax-0.050.200.05
Reported Profit After Tax2.471.75-1.62
Extra-ordinary Items 0.000.00-0.01
Adjusted Profit After Extra-ordinary item2.471.75-1.61
EPS (Unit Curr.)0.690.490.50
EPS (Adj) (Unit Curr.)0.690.490.50
Calculated EPS (Unit Curr.)0.690.49-0.49
Calculated EPS (Adj) (Unit Curr.)0.690.49-0.49
Calculated EPS (Ann.) (Unit Curr.)2.771.96-1.96
Calculated EPS (Adj) (Ann.) (Unit Curr.)2.771.96-1.96
Book Value (Unit Curr.)0.000.000.00
Dividend (%)0.000.000.00
Equity35.6935.6933.09
Reserve & Surplus0.000.000.00
Face Value10.0010.0010.00
Public Shareholding (No. Of Shares)0.000.000.00
Public Shareholding (% in Equity)0.000.000.00
Pledged/Encumbered - No. of Shares0.000.000.00
Pledged/Encumbered - % in Total Promoters Holding0.000.000.00
Pledged/Encumbered - % in Total Equity0.000.000.00
Non Encumbered - No. of Shares0.000.000.00
Non Encumbered - % in Total Promoters Holding0.000.000.00
Non Encumbered - % in Total Equity0.000.000.00
PBIDTM(%)13.2915.519.64
PBDTM(%)12.0313.365.78
PATM(%)6.005.81-6.00
Dividend Per Share(Rs)0.000.000.00
Diluted EPS0.690.490.50